Optimal aspirin dose in acute coronary syndromes: An emerging consensus

James J. Dinicolantonio, Nicholas B. Norgard, Pascal Meier, Carl J. Lavie, James H. O'Keefe, Asfandyar K. Niazi, Saurav Chatterjee, Kathleen A. Packard, Fabrizio D'Ascenzo, Enrico Cerrato, Giuseppe Biondi-Zoccai, Sripal Bangalore, Flavio D. Fuchs, Victor L. Serebruany

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

Numerous clinical trials testing the efficacy of aspirin for the secondary prevention of cardiovascular disease have been published. We reviewed the literature pertaining to aspirin dose in acute coronary syndrome patients. Clinical trials assessing the comparative efficacy of different doses of aspirin are scarce. This complex antiplatelet therapy landscape makes it difficult to identify the best aspirin dose for optimizing efficacy and minimizing risk of adverse events, while complying with the various guidelines and recommendations. Despite this fact, current evidence suggests that aspirin doses of 75-100 mg/day may offer the optimal benefit:risk ratio in acute coronary syndrome patients.

Original languageEnglish (US)
Pages (from-to)291-300
Number of pages10
JournalFuture Cardiology
Volume10
Issue number2
DOIs
StatePublished - Mar 2014

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Optimal aspirin dose in acute coronary syndromes: An emerging consensus'. Together they form a unique fingerprint.

  • Cite this

    Dinicolantonio, J. J., Norgard, N. B., Meier, P., Lavie, C. J., O'Keefe, J. H., Niazi, A. K., Chatterjee, S., Packard, K. A., D'Ascenzo, F., Cerrato, E., Biondi-Zoccai, G., Bangalore, S., Fuchs, F. D., & Serebruany, V. L. (2014). Optimal aspirin dose in acute coronary syndromes: An emerging consensus. Future Cardiology, 10(2), 291-300. https://doi.org/10.2217/fca.14.7